{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:05:31Z","timestamp":1769094331827,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pandemic events often trigger a surge of clinical trial activity aimed at rapidly evaluating therapeutic or preventative interventions. Ensuring rapid public access to the complete and unbiased trial record is particularly critical for pandemic research given the urgent associated public health needs. The World Health Organization (WHO) established standards requiring posting of results to a registry within 12\u00a0months of trial completion and publication in a peer reviewed journal within 24\u00a0months of completion, though compliance with these requirements among pandemic trials is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This cross-sectional analysis characterizes availability of results in trial registries and publications among registered trials performed during the 2009 H1N1 influenza, 2014 Ebola, and 2016 Zika pandemics. We searched trial registries to identify clinical trials testing interventions related to these pandemics, and determined the time elapsed between trial completion and availability of results in the registry. We also performed a comprehensive search of MEDLINE via PubMed, Google Scholar, and EMBASE to identify corresponding peer reviewed publications. The primary outcome was the compliance with either of the WHO\u2019s established standards for sharing clinical trial results. Secondary outcomes included compliance with both standards, and assessing the time elapsed between trial completion and public availability of results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three hundred thirty-three trials met eligibility criteria, including 261 H1N1 influenza trials, 60 Ebola trials, and 12 Zika trials. Of these, 139 (42%) either had results available in the trial registry within 12\u00a0months of study completion or had results available in a peer-reviewed publication within 24\u00a0months. Five trials (2%) met both standards. No results were available in either a registry or publication for 59 trials (18%). Among trials with registered results, a median of 42\u00a0months (IQR 16\u201376\u00a0months) elapsed between trial completion and results posting. For published trials, the median elapsed time between completion and publication was 21\u00a0months (IQR 9\u201334\u00a0months). Results were available within 24\u00a0months of study completion in either the trial registry or a peer reviewed publication for 166 trials (50%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Very few trials performed during prior pandemic events met established standards for the timely public dissemination of trial results.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12874-021-01324-8","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T10:04:41Z","timestamp":1623146681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials"],"prefix":"10.1186","volume":"21","author":[{"given":"Christopher W.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda C.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel P.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Saracco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen R.","family":"Stesis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Cavanaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy F.","family":"Platts-Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"1324_CR1","unstructured":"ClinicalTrials.gov: Summary of Listed COVID-19 Studies: U.S. National Library of Medicine; [December 11, 2020]. Available from: https:\/\/clinicaltrials.gov\/ct2\/covid_view."},{"issue":"4","key":"1324_CR2","doi-asserted-by":"publisher","first-page":"e1001819","DOI":"10.1371\/journal.pmed.1001819","volume":"12","author":"VS Moorthy","year":"2015","unstructured":"Moorthy VS, Karam G, Vannice KS, Kieny MP. Rationale for WHO\u2019s new position calling for prompt reporting and public disclosure of interventional clinical trial results. PLoS Med. 2015;12(4):e1001819.","journal-title":"PLoS Med"},{"key":"1324_CR3","unstructured":"WHO Statement on Public Disclosure of Clinical Trial Results: World Health Organization; 2015 [March 10, 2018]. Available from: https:\/\/www.who.int\/ictrp\/results\/WHO_Statement_results_reporting_clinical_trials.pdf."},{"key":"1324_CR4","doi-asserted-by":"publisher","first-page":"j2372","DOI":"10.1136\/bmj.j2372","volume":"357","author":"DB Taichman","year":"2017","unstructured":"Taichman DB, Sahni P, Pinborg A, Peiperl L, Laine C, James A, et al. Data sharing statements for clinical trials. BMJ. 2017;357:j2372.","journal-title":"BMJ"},{"key":"1324_CR5","unstructured":"NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information. Notice Number: NOT-OD-16\u2013149.: National Institutes of Health; [December 11, 2020]. Available from: https:\/\/grants.nih.gov\/grants\/guide\/notice-files\/not-od-16-149.html."},{"key":"1324_CR6","doi-asserted-by":"publisher","first-page":"f6104","DOI":"10.1136\/bmj.f6104","volume":"347","author":"CW Jones","year":"2013","unstructured":"Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF. Non-publication of large randomized clinical trials: cross sectional analysis. BMJ. 2013;347:f6104.","journal-title":"BMJ"},{"issue":"24","key":"1324_CR7","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1001\/jama.2020.8920","volume":"323","author":"FS Collins","year":"2020","unstructured":"Collins FS, Stoffels P. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA. 2020;323(24):2455\u20137.","journal-title":"JAMA"},{"issue":"5","key":"1324_CR8","doi-asserted-by":"publisher","first-page":"e1000272","DOI":"10.1371\/journal.pmed.1000272","volume":"7","author":"W Xing","year":"2010","unstructured":"Xing W, Hejblum G, Leung GM, Valleron AJ. Anatomy of the epidemiological literature on the 2003 SARS outbreaks in Hong Kong and Toronto: a time-stratified review. PLoS Med. 2010;7(5):e1000272.","journal-title":"PLoS Med"},{"issue":"9","key":"1324_CR9","doi-asserted-by":"publisher","first-page":"e041276","DOI":"10.1136\/bmjopen-2020-041276","volume":"10","author":"CW Jones","year":"2020","unstructured":"Jones CW, Woodford AL, Platts-Mills TF. Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis. BMJ Open. 2020;10(9):e041276.","journal-title":"BMJ Open"},{"key":"1324_CR10","doi-asserted-by":"crossref","unstructured":"Wilder-Smith A, Osman S. Public health emergencies of international concern: a historic overview. J Travel Med. 2020;27(8):1\u20133.","DOI":"10.1093\/jtm\/taaa227"},{"key":"1324_CR11","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhao W, Sun B, Huang Y, Glanzel W. How scientific research reacts to international public health emergencies: a global analysis of response patterns. Scientometrics. 2020:1\u201327.","DOI":"10.1007\/s11192-020-03531-4"},{"key":"1324_CR12","unstructured":"Clinical Trials: World Health Organization; [February 6, 2019]. Available from: https:\/\/www.who.int\/topics\/clinical_trials\/en\/."},{"key":"1324_CR13","unstructured":"International Clinical Trials Registry Platform (ICTRP): Primary Registries: World Health Organization. Available from: https:\/\/www.who.int\/ictrp\/network\/primary\/en\/."},{"key":"1324_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12916-015-0520-3","volume":"13","author":"CW Jones","year":"2015","unstructured":"Jones CW, Keil LG, Holland WC, Caughey MC, Platts-Mills TF. Comparison of registered and published outcomes in randomized controlled trials: a systematic review. BMC Med. 2015;13:282.","journal-title":"BMC Med"},{"issue":"7","key":"1324_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/M13-0480","volume":"160","author":"DM Hartung","year":"2014","unstructured":"Hartung DM, Zarin DA, Guise JM, McDonagh M, Paynter R, Helfand M. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. Ann Intern Med. 2014;160(7):477\u201383.","journal-title":"Ann Intern Med"},{"key":"1324_CR16","unstructured":"Clinical Trials Registration and Results Information Submission; Final rule: National Institutes of Health, Department of Health and Human Services; 2016 [11\/30\/2020]. 81 FR 64981:[Available from: https:\/\/www.federalregister.gov\/documents\/2016\/09\/21\/2016-22129\/clinical-trials-registration-and-results-information-submission"},{"key":"1324_CR17","unstructured":"Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank: U.S. Department of Health and Human Services Food and Drug Administration; 2020 [11\/20\/2020]. 1-12]. Available from: https:\/\/www.fda.gov\/media\/113361\/download"},{"key":"1324_CR18","doi-asserted-by":"publisher","first-page":"g3058","DOI":"10.1136\/bmj.g3058","volume":"348","author":"L Manzoli","year":"2014","unstructured":"Manzoli L, Flacco ME, D\u2019Addario M, Capasso L, De Vito C, Marzuillo C, et al. Non-publication and delayed publication of randomized trials on vaccines: survey. BMJ. 2014;348:g3058.","journal-title":"BMJ"},{"issue":"11","key":"1324_CR19","doi-asserted-by":"publisher","first-page":"e1002966","DOI":"10.1371\/journal.pmed.1002966","volume":"16","author":"CA Rees","year":"2019","unstructured":"Rees CA, Pica N, Monuteaux MC, Bourgeois FT. Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis. PLoS Med. 2019;16(11):e1002966.","journal-title":"PLoS Med"},{"issue":"18","key":"1324_CR20","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2020.17195","volume":"324","author":"M Malicki","year":"2020","unstructured":"Malicki M, Jeroncic A, Ter Riet G, Bouter LM, Ioannidis JPA, Goodman SN, et al. Preprint Servers\u2019 Policies, Submission Requirements, and Transparency in Reporting and Research Integrity Recommendations. JAMA. 2020;324(18):1901\u20133.","journal-title":"JAMA"},{"key":"1324_CR21","unstructured":"Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19: University of Oxford; 2020 [1\/6\/2021]. Available from: https:\/\/www.recoverytrial.net\/news\/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19."},{"key":"1324_CR22","unstructured":"Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19: Gilead; 2020 [1\/06\/2021]. Available from: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/6\/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19."},{"key":"1324_CR23","doi-asserted-by":"publisher","unstructured":"Ward BJ, Gobeil P, Seguin A, Atkins J, Boulay I, Charbonneau P, et al. Phase 1 trial of a candidate recombinant virus-like particle vaccine for Covid-19 disease produced in plants. medRxiv. 2020.\u00a0https:\/\/doi.org\/10.1101\/2020.11.04.20226282.","DOI":"10.1101\/2020.11.04.20226282"},{"issue":"10","key":"1324_CR24","doi-asserted-by":"publisher","first-page":"e0240123","DOI":"10.1371\/journal.pone.0240123","volume":"15","author":"S Gianola","year":"2020","unstructured":"Gianola S, Jesus TS, Bargeri S, Castellini G. Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic. PLoS ONE. 2020;15(10):e0240123.","journal-title":"PLoS ONE"},{"issue":"7552","key":"1324_CR25","first-page":"1232","volume":"332","author":"R Watson","year":"2006","unstructured":"Watson R. WHO calls for registration of all clinical trials. BMJ. 2006;332(7552):1232.","journal-title":"BMJ"},{"issue":"11","key":"1324_CR26","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/jama.292.11.1363","volume":"292","author":"CD DeAngelis","year":"2004","unstructured":"DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004;292(11):1363\u20134.","journal-title":"JAMA"},{"issue":"7","key":"1324_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jclinepi.2015.01.027","volume":"68","author":"RW Scherer","year":"2015","unstructured":"Scherer RW, Ugarte-Gil C, Schmucker C, Meerpohl JJ. Authors report lack of time as main reason for unpublished research presented at biomedical conferences: a systematic review. J Clin Epidemiol. 2015;68(7):803\u201310.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"1324_CR28","doi-asserted-by":"publisher","first-page":"e110418","DOI":"10.1371\/journal.pone.0110418","volume":"9","author":"F Song","year":"2014","unstructured":"Song F, Loke Y, Hooper L. Why are medical and health-related studies not being published? A systematic review of reasons given by investigators. PLoS ONE. 2014;9(10):e110418.","journal-title":"PLoS ONE"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-021-01324-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-021-01324-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-021-01324-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T10:04:59Z","timestamp":1623146699000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-021-01324-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1186\/s12874-021-01324-8","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CWJ has received research grants from Janssen, Hologic, AstraZeneca, and Vapotherm unrelated to this work. Dr. Platts-Mills is employed by Quantworks Inc, which had no role in the submitted work; the authors declare no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}